Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders

In brief

This study will randomized hematology oncology patients with active diarrhea and a NAAT positive/toxin EIA negative to either 14 days of oral vancomycin capsules or placebo. The study is designed to include 30 patients (15 per arm). Outcomes will include C. difficile load using qPCR, VRE loads, structural and functional microbiome changes and frequency of bowel movements. All endpoints will be measured at several time points including days 0, 14, 21 and 90.

Key facts

Study ID
NCT03030248
Run by
Medical College of Wisconsin
People needed
9
Starts
2018-06-01
Expected to finish
2020-06-30
Last updated by the study team
2026-04-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.